May 27, 2013
To whom it may concern:
Company Name : TOHO HOLDINGS CO., LTD.
Representative : Norio Hamada /President and Representative Director(Securities Code: 8129 / First Section of Tokyo Stock Exchange)
Contact: Katsuya Kato
Corporate Officer and General Manager ofCorporate Communications Officeand Corporate Planning Office(TEL: 03-5259-9520)

Notice Regarding the Business Integration of Five Sub-subsidiaries
TOHO HOLDINGS CO., LTD. is pleased to announce that the meeting of its Board of Directors held today(May 27, 2013) resolved to commence consultations towards a business merger among the Company’s fivewholly-owned sub-subsidiaries, Tomonity Inc. (hereinafter “Tomonity”), Pharma Square Co., Ltd.
(hereinafter “Pharma Square”), Mirai Corporation (hereinafter “Mirai”), Nest Co., Ltd. (hereinafter “Nest”)
and Jus-Pharma Co., Ltd. (hereinafter “Jus-Pharma”) on November 1, 2013 (planned). An outline is asfollows.
It should be noted that, because the business consolidation only involves the Company’s wholly-owned
consolidated sub-subsidiaries, the disclosures that would otherwise be required are provided herein withcertain omissions.

1.

Purpose of consolidation
The Group adopts a business management and control system under which our wholly-owned
subsidiary PharmaCluster Co., Ltd. plays a central role in dispensing pharmacy businesses. However,
the Company considers that its five wholly-owned sub-subsidiaries of Tomonity, Pharma Square, Mirai,
Nest and Jus-Pharma will be able to further reinforce the pharmacy functions and maximize the Group
companies’ corporate value by actively utilizing the Group’s management resources, and has
consequently decided that each company should commence consultations towards business merger. Inaddition, the Company will continue to discuss the business reorganization within the Group tostrengthen the management base of the dispensing pharmacy business.

2.

Objectives of consolidation(1) Schedule of consolidation
The end of July 2013
November 1, 2013

The agreement of consolidation (planned)
Date of consolidation (planned)(2) Method of consolidation / Details of share allotment
The method of consolidation and details of the share allotment will be specified in the near future after
consultations by the Group companies in charge of the operation and management of the dispensing
pharmacies, including the Company and PharmaCluster Co., Ltd.

13.

Outlines of parties involved in the consolidation(1) Company name Tomonity Inc.
(2) Business
Dispensing Pharmacy Businesscontents(3) Establishment
July 7, 1993
(4) Principal place
4-4-2, Honcho, Nihonbashi,Chuo-ku, Tokyo(5) Corporate
Toshiyuki Tsukuda
representative(6) Capital
50 million yen(7) Number of
400,000
shares issued(8) Fiscal year end
March 31

Pharma Square Co., Ltd.
Dispensing Pharmacy Business
July 1, 1989
4-4-2, Honcho, Nihonbashi,Chuo-ku, Tokyo
Katsuhiro Yoshimoto
50 million yen
100,000
March 31(9) Majorshareholders andequity holdings

PharmaCluster Co., Ltd. 100％

PharmaCluster Co., Ltd. 100％

(1) Company name(2) Businesscontents(3) Establishment(4) Principal place

Mirai Corporation
Dispensing Pharmacy Business

Nest Co., Ltd.
Dispensing Pharmacy Business

March 31, 1981
3-5-13, Heijima, Nishi-ku, Niigata
city, Niigata
Takeshi Kurita

April 30, 2010
1-3-7, Kimachidori,
Sendai city, Miyagi
Masao Motohashi

36 million yen
900

50 million yen
1,000

March 31

March 31(9) Major
shareholders andequity holdings

PharmaCluster Co., Ltd. 100％

PharmaCluster Co., Ltd. 100％

(1) Company name(2) Businesscontents(3) Establishment(4) Principal place

Jus-Pharma Co., Ltd.
Dispensing Pharmacy Business(5) Corporate
representative(6) Capital(7) Number ofshares issued(8) Fiscal year end(5) Corporate
representative(6) Capital(7) Number ofshares issued(8) Fiscal year end(9) Major
shareholders andequity holdings

November 11, 1989
3-4139-11, Ishikawa, Mito city,
Ibaraki
Sadao Kimura
10 million yen
10,000March 31
PharmaCluster Co., Ltd. 100％2Aoba-ku,

4.

Effects of consolidationThe trade name, location of the main office, the title and the name of the representatives, the amount ofcapital and the term for the settlement of accounts will be decided after consultations among the relatedparties, including the Company and PharmaCluster Co., Ltd.

5.

Outlook
Since the planned consolidation is a part of the Group’s reorganization involving only the Company’s
wholly-owned sub-subsidiaries, the impact it will have on the Company’s consolidated financial results
for the fiscal year ending March 2014 is expected to be minimal.

3